Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Jazz Pharmaceuticals Ireland Limited has 6 pending office actions in Biotechnology & Pharmaceuticals, distributed among 6 examiners and 4 art units. OTTON, ALICIA L is the busiest named examiner, with 1 pending matter.
The distribution indicates that prosecution management is spread across several examination contexts rather than centered on one examiner. Counsel may need matter-specific strategies for claim scope, prior-art analysis, and response timing, while coordinating positions across related pharmaceutical filings where appropriate.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353770 | BIARYL ETHER UREA COMPOUNDS | REDWOOD, CHRISTOPHER EVAN | 89d overdue |
| 18727926 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SEAMAN, D MARGARET M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294129 | METHOD OF TREATING POSTTRAUMATIC STRESS DISORDER | BELL, SARA ELIZABETH | 21d |
| Art Unit | Apps |
|---|---|
| 1629 | 3 |
| 1625 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869941 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | OTTON, ALICIA L | 1629 | §112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18849340 | TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18727976 | METHOD OF ADMINISTERING OXYBATE | WEDDINGTON, KEVIN E | 1629 | DPOther | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18727926 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SEAMAN, D MARGARET M | 1625 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18294129 | METHOD OF TREATING POSTTRAUMATIC STRESS DISORDER | BELL, SARA ELIZABETH | 1625 | §103 | Non-Final OA | 21d | Pending | Jan 31, 2024 |
| 18353770 | BIARYL ETHER UREA COMPOUNDS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103Other | Final Rejection | 89d overdue | Pending | Jul 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJazz Pharmaceuticals Ireland Limited has 6 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Alicia L Otton has the most, with 1 of Jazz Pharmaceuticals Ireland Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
